FDA Grants Accelerated Approval to AstraZeneca's Camizestrant Combo for Advanced Breast Cancer

The FDA granted accelerated approval to AstraZeneca's camizestrant (Ectamah) in combination with a CDK4/6 inhibitor for eligible advanced breast cancer patients. This marks a regulatory milestone for the drug, though confirmatory trials are likely required. The approval expands treatment options in a competitive oncology market, potentially affecting AstraZeneca's revenue outlook.